Effects of simvastatin on pro-inflammatory cytokines in patients with hypercholesterolemia;Prozapalne cytokiny w hipercholesterolemii: Działanie simwastatyny

Kardiologia Polska

Volumn 59, Issue 12, 2003, Pages 465-474

  Zubelewicz Szkodzińska, Barbara ^a,b   Szkodziński, Janusz ^a   Danikiewicz, Aleksander ^a   Romanowski, Wojciech ^a   Błazelonis, Adam ^a   Muc Wierzgoń, Małgorzata ^a   Piȩtka Rzycka, Anna ^a   Muryn, Zuzanna ^a   Wysocki, Henryk ^c  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Katedra I Oddzia Kliniczny Chorob Wewnetrznych Angiologii I Medycyny Fizykalnej   (Poland)

^c Kated Klin Intens Terap Kardiol   (Poland)

Author keywords

Cytokines; Hypercholesterolemia; IL 2; Simvastatin; TNF

Indexed keywords

CHOLESTEROL; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; VASCULAR ENDOTHELIUM;

EID: 17044446441     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ross R.: Atherosclerosis an inflammatory disease. N. Eng. J. Med. 1999, 340, 115-126.
2. Shah P.K.: Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. Circulation 2000, 101, 1758-1759.
3. Bendtzen K.: Cytokines and natural regulators of cytokines. Immunol. Lett. 1994, 43, 111-123.
4. Ridker P.M., Rifai N., Stampfer M. et al.: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101, 1767-1772.
5. Libby P.: What have we learned about the biology of atherosclerosis? The role of inflammation. Am. J. Cardiol. 2001, 88 (suppl), 3J-6J.
6. Kelley D.S., Simon V.A., Taylor P.C. et al.: Dietary supplementation with conjugated linoleic acid increased its concentration in human peripheral blood mononuclear cells, but did not alter their function. Lipids 2001, 36 (7), 669-674.
7. Strandberg T.E., Vanhanen H., Tikkanen M.J.: Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999, 353, 118-9.
8. Rosenson R.S., Tangney C.C., Casey L.C.: Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999, 353, 983-4.
9. Musial J., Undas A., Gajewski P. et al.: Anti-inflammatory effects of simvastatin in subject with hypercholesterolemia. Int. J. Cardiology 2001, 247-253.
10. Ferro D., Parrotto S., Basili S. et al.: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J. Am. Coll. Cardiol. 2000, 36, 427-31.
11. Togashi N., Ura N., Higashiura K. et al.: Effect of TNF alpha converting enzyme inhibitor on insulin resistance in fructose fed rats. Hypertension 2002, 39 (2 Pt 2), 578-80.
12. Calder P.C.: n-3-polyunsaturated fatty acids and cytokine production in health and disease. Ann. Nutr. Metab. 1997, 41 (4), 203-34.
13. Han S.N., Leka L.S., Lichtenstein A.H. et al.: Effects of hydrogenated and saturated, relafive and polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J. Lipid Res. 2002, 43 (3), 445-52.
14. Ando H., Takamura T., Ota T. et al.: Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J. Pharmacol. Exp. Ther. 2000, 294 (3), 1043-6.
15. Grip O., Janciauskiene S., Lindgren S.: Pravastafin down-regulates inflammatory mediators in human monocytes in vitro. Eur. J. Pharmacol. 2000, 410 (1), 83-92.
16. Mohrschladt M.F., Weverling-Rijnsburger A.W., de Man F.H. et al.: Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. Atherosclerosis 2000, 148, 413-419.
17. Weis M., Pehlivanli S., Meiser B.M. et al.: Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J. Am. Cardiol. 2001, 38 (3), 814-8.
18. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl. J. Med. 1998, 339, 1349-57.
19. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344, 1383-9.
20. Sacks F.M., Pfeffer M.A., Moye L.A.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 1996, 335, 1001-9.